Invention Grant
![Substituted pyrrolo[3,4-d]pyrimidines as kinase inhibitors](/docs/US/2017-01-17/US09546173B2/abs.jpg.600x600.jpg)
- Patent Title: Substituted pyrrolo[3,4-d]pyrimidines as kinase inhibitors
- Patent Title (中): 取代的吡咯并[3,4-d]嘧啶作为激酶抑制剂
-
Application No.: US14428546Application Date: 2013-09-17
-
Publication No.: US09546173B2Publication Date: 2017-01-17
- Inventor: Michael Patrick Dillon , Mika Lindvall , Daniel Poon , Savithri Ramurthy , Vivek Rauniyar , Cynthia Shafer , Sharadha Subramanian , Huw Rowland Tanner
- Applicant: Michael Patrick Dillon , Mika Lindvall , Daniel Poon , Savithri Ramurthy , Vivek Rauniyar , Cynthia Shafer , Sharadha Subramanian , Huw Rowland Tanner
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agent Shawn D. Britt
- International Application: PCT/US2013/060032 WO 20130917
- International Announcement: WO2014/047020 WO 20140327
- Main IPC: A61K31/519
- IPC: A61K31/519 ; C07D239/70 ; C07D487/04 ; C07D207/36 ; A61K31/527 ; A61K45/06 ; C07D487/10
![Substituted pyrrolo[3,4-d]pyrimidines as kinase inhibitors](/abs-image/US/2017/01/17/US09546173B2/abs.jpg.150x150.jpg)
Abstract:
The present invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof; as further described herein. The present invention further provides pharmaceutical compositions comprising these compounds, and combinations comprising these compounds combined with or used with a therapeutic co-agent, as well as therapeutic uses of these compounds and compositions. These are useful in the treatment of diseases such as cancer that are associated with activation of ERK1 and/or ERK2, and especially for MAPK pathway dependent cancers showing resistance to Raf and/or MEK inhibitory cancer therapeutics.
Public/Granted literature
- US20150274733A1 DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS Public/Granted day:2015-10-01
Information query
IPC分类:
